Gatehouse Bio is a bio-data company in collaboration with AstraZeneca for the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bio’s AI-powered platform. The sRNAlytics platform identifies small RNA (sRNA) signatures in sequencing data and points to molecular pathways that correlate to or potentially drive disease.
Timeline
Funding Rounds
Patents
Further Resources
Title
Author
Link
Type
Date
References
3
Type: Web page
https://gatehousebio.com/about-us/4
Type: Web page
https://gatehousebio.com/about-us/5
Type: Web page
https://gatehousebio.com/about-us/6
Type: Web page
https://gatehousebio.com/contact-us/
Organization
CompanyCompany attributes
RNA
Therapeutics
In-vitro diagnostics (IVD)
Healthcare
Drug discoveryLocation
Natick, MassachusettsB2X
B2BCEO
Founder
Pitchbook URL
Legal Name
sRNAlytics, LLC
Accelerator
IndieBioAccelerator Batch
Legal classification
Limited liability companyNumber of Employees (Ranges)
20 – 49
SOSVFounded Date
April 16, 2016
Total Funding Amount (USD)
5,445,379
Latest Funding Round Date
January 2021
Also Known As
sRNAlytics
Latest Funding Type
Seed round
United States